- Home
- MRM vs LSTA Comparison
MRM vs LSTA Comparison
Compare MRM & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRM | LSTA |
|---|---|---|
| Founded | 2000 | 1980 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Misc Health and Biotechnology Services |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.8M | 16.4M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | MRM | LSTA |
|---|---|---|
| Price | $1.34 | $4.54 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 49.8K | ★ 389.2K |
| Earning Date | 05-22-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $55,915,220.00 | $1,070,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $31.54 | ★ N/A |
| Revenue Growth | ★ 12.79 | N/A |
| 52 Week Low | $0.34 | $1.81 |
| 52 Week High | $4.45 | $4.89 |
Technical Indicators
Market Signals| Indicator | MRM | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 17.53 | 79.62 |
| Support Level | $1.21 | $4.48 |
| Resistance Level | $1.73 | $4.79 |
| Average True Range (ATR) | 0.09 | 0.15 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 23.02 | 60.79 |
Price Performance
Historical ComparisonAbout MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.